Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Oregon Health and Science University | OTHER |
Not provided
Not provided
Not provided
Not provided
A prospective, open-label study of PKU Sphere in patients with PKU following a phenylalanine restricted therapeutic diet.
The rationale for this study is to assess acceptability, adherence and metabolic control in individuals with PKU consuming PKU Sphere, a GMP-based medical food.
The sponsor developed PKU Sphere in response to growing interest in GMP medical foods for the purpose of improving adherence and quality of life by offering an alternative to amino acid based medical foods. PKU Sphere is a powdered, low phenylalanine medical food containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid (DHA). PKU Sphere has been designed for use in the dietary management of Phenylketonuria. It is available in two flavors, Red Berry and Vanilla, packaged in individual serving sachets of 35g and containing 20g protein equivalent (PE).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PKU Sphere | Experimental | Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis. Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PKU Sphere | Dietary Supplement | PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: taste | Questionnaire data captured to evaluate taste | Days 1 - 7. |
| Phase 1: smell | Questionnaire data captured to evaluate smell | Days 1 - 7. |
| Phase 1: texture | Questionnaire data captured to evaluate texture | Days 1 - 7. |
| Phase 1: gastrointestinal tolerance | Questionnaires will be completed daily during the 1-week taste test. | Days 1 - 7. |
| Phase 1: phenylalanine concentration | Phenylalanine concentrations measured via blood spot analysis. | Days 1 and 7. |
| Phase 1: tyrosine concentration | Tyrosine concentrations measured via blood spot analysis. | Days 1 and 7. |
| Phase 2: quantitative change in plasma amino acids at day 28 | Compare comprehensive plasma amino acid profiles at baseline and end of the trial. | Phase 2, day 1 and day 28. |
| Phase 2: gastrointestinal tolerance | Questionnaires will be completed daily throughout Phase 2. | Phase 2, days 1 - 28. |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: questoinnaire evaluating subjective measures of satiety | To evaluate if PKU Sphere increases subjective measures of satiety | Phase 1, days 1 - 7. |
| Phase 2: questoinnaire evaluating subjective measures of satiety |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sandra Van Calcar, PhD | Oregon Health and Science University | Principal Investigator |
| Joyanna Hansen, PhD | Oregon Health and Science University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health and Science University | Portland | Oregon | 97239 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010661 | Phenylketonurias |
| ID | Term |
|---|---|
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Two phase study consisting of a 1 week taste introduction period followed by a 4 week period assessing acceptability and metabolic control.
Not provided
Not provided
Not provided
Not provided
| Phase 2: change in 3-day diet record at end of study | A 3-day diet record will be completed in the first 3 days and the last 3 days for comparison. | Phase 2, days 1 - 3 and days 26 - 28. |
| Phase 2: change in anthropometry at end of study | Participants will be weighed and measured, a growth chart plotted (children only), and BMI calculated | Phase 2, days 1 and 28. |
| Phase 2: phenylalanine concentration | Phenylalanine concentrations measured via blood spot analysis. | Twice weekly for four weeks during phase 2 |
| Phase 2: tyrosine concentration | Tyrosine concentrations measured via blood spot analysis. | Twice weekly for four weeks during phase 2 |
| Phase 2: questionnaire data captured to evaluate change in taste perception | Data captured to evaluate taste | Phase 2, days 14 and 28. |
| Phase 2: questionnaire data captured to evaluate change in smell perception | Data captured to evaluate smell | Phase 2, days 14 and 28. |
| Phase 2: questionnaire data captured to evaluate change in texture perception | Data captured to evaluate texture | Phase 2, days 14 and 28. |
To evaluate if PKU Sphere increases subjective measures of satiety
| Phase 2, days 1, 14 and 28. |
| D009422 | Nervous System Diseases |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |